Integrated analysis of pooled trial data in 3652 patients with ulcerative colitis or relapsing multiple sclerosis (16,144 patient-years, up to 10 years): ozanimod showed low rates of serious infection (1.0/100 PY) and malignancy (0.4/100 PY), with no new safety signals.
Meta-analysisn = 3,652
Rubin et al. Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis